An unusual association in a patient with COVID-19-related ARDS and bilateral pleural effusion
Abstract
Keywords
Full Text:
PDFReferences
References
1. Baughman, R.P., Lower, E.E. (2021). COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 38(2), e2021029. doi: 10.36141/svdld.v38i2.11646.
2. Ji, X., Lu, J., Zuo, A., Sun, F., Peng, H., Lu, D. (2022) Pleural involvements in pulmonary sarcoidosis: A case report and review of the literature. Front. Med.(9), 902711. doi: 10.3389/fmed.2022.902711.
3. Chong, W.H., Saha, B.K., Conuel, E., Chopra, A. (2021). The incidence of pleural effusion in COVID-19 pneumonia: State-of-the-art review. Heart Lung. 50(4), 481-490. doi: 10.1016/j.hrtlng.2021.02.015.
4. Rathore, S.S., Hussain, N., Manju, A.H., Wen, Q., Tousif, S., Avendaño-Capriles, C.A., Hernandez-Woodbine, M.J., Rojas, G.A., Vatsavayi, P., Tera, C.R., Ali, M.A., Singh, R., Saleemi, S., Patel, D.M. (2022). Prevalence and clinical outcomes of pleural effusion in COVID-19 patients: A systematic review and meta-analysis. J Med Virol.94(1), 229-239. doi: 10.1002/jmv.27301.
5. Duong, H.T., Bonham, C.A. (2018). Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis and treatment. ClinPulm Med. 25(2),52-60.doi:10.1097/CPM.0000000000000252
6. Mirsaeidi, M., Omar, H.R., Baughman, R., Machado, R., Sweiss, N. (2016). The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis.33(4),317-320.
7. Ichinose, A., Otani, H., Oikawa, M., Takase, K., Saito, H., Shimokawa, H., Takahashi, S. (2008). MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol. 191(3),862-9. doi: 10.2214/AJR.07.3089.
8. Kiko, T., Yoshihisa, A., Kanno, Y., Yokokawa, T., Abe, S., Miyata-Tatsumi, M., Misaka, T., Oikawa, M., Kobayashi, A., Ishida, T., Takeishi, Y. (2018). A Multiple Biomarker Approach in Patients with Cardiac Sarcoidosis. Int Heart J.59(5),996-1001. doi: 10.1536/ihj.17-695.
9. Darlington, P., Gabrielsen, A., Cederlund, K., Kullberg, S., Grunewald, J., Eklund, A., Sörensson P. (2019). Diagnostic approach for cardiac involvement in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 36(1),11-17. doi: 10.36141/svdld.v36i1.7132.
10. Dökümcü, E. (2021). The role of carbohydrate antigen 125 in COVID-19. Med Hypotheses.151:110590. doi: 10.1016/j.mehy.2021.110590.
11. Ros-Lucas, J.A., Pascual-Figal, D.A., Noguera-Velasco, J.A., Hernández-Vicente, Á., Cebreiros-López, I., Arnaldos-Carrillo, M., Martínez-Ardil, I.M., García-Vázquez, E., Aparicio-Vicente, M., Solana-Martínez, E., Ruiz-Martínez, S.Y., Fernández-Mula, L., Andujar-Espinosa, R., Fernández-Suarez, B., Sánchez-Caro, M.D., Peñalver-Mellado, C., Ruiz-López, F.J. (2022). CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia. Sci Rep.(1):6738. doi: 10.1038/s41598-022-10726-7.
12.Kalluri, M., Judson, M.A. (2007). Sarcoidosis associated with an elevated serum CA 125 level: description of a case and a review of the literature. Am J Med Sci. 334(6):441-3. doi: 10.1097/MAJ.0b013e3180f60bc4.
13. Türk, Y., Shapiro, C., Braunstahl, G.J. (2017). CA 15.3: a marker of disease activity in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 34(1):100-101. doi: 10.36141/svdld.v34i1.4786.
14. Sharma, O.P.(2000). Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med.6(5),442-7. doi: 10.1097/00063198-200009000-00010.
15. Baughman, R.P., Janovcik, J., Ray, M., Sweiss, N., Lower, E.E.(2013). Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 30(2), pp. 113-120
DOI: https://doi.org/10.13129/1828-6550/APMB.111.1.2023.CCS1
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Antonio Cipolla, Antonio Faiello, Giuseppe Ielo, Giorgio Morana, Federica Lo Bello, Alfio Proietto, Carlo Vanchieri, Gaetano Caramori
This work is licensed under a Creative Commons Attribution 4.0 International License.